Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.76 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.47 |
| ▸ | WNT3A | P56704 | 3/20 | 0.43 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332765 | 0.90 | MAPK14 (0.74) | MAPK14MAPK9MAPK10MAPK11MLYCD | |
| SCHEMBL4348749 | 0.89 | MAPK14 (0.73) | MAPK14CSNK1DMAPK10MAPK11 | |
| SCHEMBL4337049 | 0.88 | MAPK14 (0.72) | MAPK14CSNK1DMAPK10 | |
| SCHEMBL4340479 | 0.88 | MAPK14 (0.71) | MAPK14WNT3APORCNMLYCDRAB9A | |
| SCHEMBL4499322 | 0.86 | MAPK14 (0.72) | MAPK14CSNK1DMAPK10MAPK11 | |
| SCHEMBL4339804 | 0.86 | MAPK14 (0.71) | MAPK14CSNK1D | |
| SCHEMBL4343993 | 0.82 | MAPK14 (0.69) | MAPK14CSNK1DWNT3AMAPK9MAPK10 | |
| SCHEMBL4336207 | 0.81 | MAPK14 (0.78) | MAPK14CSNK1DMAPK9MAPK10MAPK11 | |
| SCHEMBL4521201 | 0.81 | MAPK14 (0.81) | MAPK14MLYCDRAB9A | |
| SCHEMBL4334980 | 0.80 | MAPK14 (0.88) | MAPK14MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885CSNK1D 285/4885WNT3A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.